inhibition of activity of 27% for S-ACP-DES5 in the presence of 5fold excess of unlabeled product oleoyl-[acyl-carrier protein]; inhibition of activity of 50% for S-ACP-DES4 in the presence of 5fold excess of unlabeled product oleoyl-[acyl-carrier protein]; inhibition of activity of 67% for S-ACP-DES3 in the presence of 5fold excess of unlabeled product oleoyl-[acyl-carrier protein] and 40% for S-ACP-DES3 in the presence of 5fold unlabeled product palmitoleoyl-[acyl-carrier protein], respectively; inhibition of activity of 73% for SSI2 in the presence of 5fold excess of unlabeled product oleoyl-[acyl-carrier protein] and 37% for SSI2 in the presence of 5fold unlabeled product palmitoleoyl-[acyl-carrier protein], respectively; inhibition of activity of 7% for S-ACP-DES1 in the presence of 5fold excess of unlabeled product oleoyl-[acyl-carrier protein]
inhibition of activity of 27% for S-ACP-DES5 in the presence of 5fold excess of unlabeled product oleoyl-[acyl-carrier protein]; inhibition of activity of 50% for S-ACP-DES4 in the presence of 5fold excess of unlabeled product oleoyl-[acyl-carrier protein]; inhibition of activity of 67% for S-ACP-DES3 in the presence of 5fold excess of unlabeled product oleoyl-[acyl-carrier protein] and 40% for S-ACP-DES3 in the presence of 5fold unlabeled product palmitoleoyl-[acyl-carrier protein], respectively; inhibition of activity of 73% for SSI2 in the presence of 5fold excess of unlabeled product oleoyl-[acyl-carrier protein] and 37% for SSI2 in the presence of 5fold unlabeled product palmitoleoyl-[acyl-carrier protein], respectively; inhibition of activity of 7% for S-ACP-DES1 in the presence of 5fold excess of unlabeled product oleoyl-[acyl-carrier protein]
inhibition of activity of 27% for S-ACP-DES5 in the presence of 5fold excess of unlabeled product oleoyl-[acyl-carrier protein]; inhibition of activity of 50% for S-ACP-DES4 in the presence of 5fold excess of unlabeled product oleoyl-[acyl-carrier protein]; inhibition of activity of 67% for S-ACP-DES3 in the presence of 5fold excess of unlabeled product oleoyl-[acyl-carrier protein] and 40% for S-ACP-DES3 in the presence of 5fold unlabeled product palmitoleoyl-[acyl-carrier protein], respectively; inhibition of activity of 73% for SSI2 in the presence of 5fold excess of unlabeled product oleoyl-[acyl-carrier protein] and 37% for SSI2 in the presence of 5fold unlabeled product palmitoleoyl-[acyl-carrier protein], respectively; inhibition of activity of 7% for S-ACP-DES1 in the presence of 5fold excess of unlabeled product oleoyl-[acyl-carrier protein]
inhibition of activity of 27% for S-ACP-DES5 in the presence of 5fold excess of unlabeled product oleoyl-[acyl-carrier protein]; inhibition of activity of 50% for S-ACP-DES4 in the presence of 5fold excess of unlabeled product oleoyl-[acyl-carrier protein]; inhibition of activity of 67% for S-ACP-DES3 in the presence of 5fold excess of unlabeled product oleoyl-[acyl-carrier protein] and 40% for S-ACP-DES3 in the presence of 5fold unlabeled product palmitoleoyl-[acyl-carrier protein], respectively; inhibition of activity of 73% for SSI2 in the presence of 5fold excess of unlabeled product oleoyl-[acyl-carrier protein] and 37% for SSI2 in the presence of 5fold unlabeled product palmitoleoyl-[acyl-carrier protein], respectively; inhibition of activity of 7% for S-ACP-DES1 in the presence of 5fold excess of unlabeled product oleoyl-[acyl-carrier protein]
inhibition of activity of 27% for S-ACP-DES5 in the presence of 5fold excess of unlabeled product oleoyl-[acyl-carrier protein]; inhibition of activity of 50% for S-ACP-DES4 in the presence of 5fold excess of unlabeled product oleoyl-[acyl-carrier protein]; inhibition of activity of 67% for S-ACP-DES3 in the presence of 5fold excess of unlabeled product oleoyl-[acyl-carrier protein] and 40% for S-ACP-DES3 in the presence of 5fold unlabeled product palmitoleoyl-[acyl-carrier protein], respectively; inhibition of activity of 73% for SSI2 in the presence of 5fold excess of unlabeled product oleoyl-[acyl-carrier protein] and 37% for SSI2 in the presence of 5fold unlabeled product palmitoleoyl-[acyl-carrier protein], respectively; inhibition of activity of 7% for S-ACP-DES1 in the presence of 5fold excess of unlabeled product oleoyl-[acyl-carrier protein]
inhibition of activity of 27% for S-ACP-DES5 in the presence of 5fold excess of unlabeled product oleoyl-[acyl-carrier protein]; inhibition of activity of 50% for S-ACP-DES4 in the presence of 5fold excess of unlabeled product oleoyl-[acyl-carrier protein]; inhibition of activity of 67% for S-ACP-DES3 in the presence of 5fold excess of unlabeled product oleoyl-[acyl-carrier protein] and 40% for S-ACP-DES3 in the presence of 5fold unlabeled product palmitoleoyl-[acyl-carrier protein], respectively; inhibition of activity of 73% for SSI2 in the presence of 5fold excess of unlabeled product oleoyl-[acyl-carrier protein] and 37% for SSI2 in the presence of 5fold unlabeled product palmitoleoyl-[acyl-carrier protein], respectively; inhibition of activity of 7% for S-ACP-DES1 in the presence of 5fold excess of unlabeled product oleoyl-[acyl-carrier protein]
inhibition of activity of 27% for S-ACP-DES5 in the presence of 5fold excess of unlabeled product oleoyl-[acyl-carrier protein]; inhibition of activity of 50% for S-ACP-DES4 in the presence of 5fold excess of unlabeled product oleoyl-[acyl-carrier protein]; inhibition of activity of 67% for S-ACP-DES3 in the presence of 5fold excess of unlabeled product oleoyl-[acyl-carrier protein] and 40% for S-ACP-DES3 in the presence of 5fold unlabeled product palmitoleoyl-[acyl-carrier protein], respectively; inhibition of activity of 73% for SSI2 in the presence of 5fold excess of unlabeled product oleoyl-[acyl-carrier protein] and 37% for SSI2 in the presence of 5fold unlabeled product palmitoleoyl-[acyl-carrier protein], respectively; inhibition of activity of 7% for S-ACP-DES1 in the presence of 5fold excess of unlabeled product oleoyl-[acyl-carrier protein]